LYEL Lyell Immunopharma, Inc
Price Chart
Executive Summary
Lyell Immunopharma reported its Q4 and full-year 2025 financial results, highlighted by reduced net losses compared to the prior year, ongoing pivotal trials for ronde-cel in lymphoma, clinical progress with LYL273 in colorectal cancer, and a $50 million equity tranche closing. The company has $247.2 million in cash as of year-end 2025, with runway into Q2 2027.
Key Financial Metrics
Actionable Insight
The narrowing losses and extended cash runway into Q2 2027 reduce near-term dilution risk. Upcoming catalysts include mid-2027 pivotal data from PiNACLE trial supporting a potential BLA filing. Monitor progress in PiNACLE-H2H and LYL273 dose escalation for further de-risking.
Key Facts
- Net loss narrowed to $140.7M in Q4 2025 from $191.9M in Q4 2024; full-year loss decreased to $274.4M from $343.0M in 2024.
- Cash, cash equivalents, and marketable securities were $247.2M as of December 31, 2025, excluding $50M raised in March 2026.
- Patient dosing has commenced in the Phase 3 head-to-head PiNACLE-H2H trial of ronde-cel vs. axi-cel or liso-cel in 2L large B-cell lymphoma.
- Seven new patients treated with LYL273 in mCRC since acquisition, with no dose-limiting toxicity and escalation to Dose Level 3.
- Ronde-cel showed 93% best overall response rate and 76% complete response rate in 29 efficacy-evaluable patients in the 3L+ setting.
- Second $50M tranche of $100M private placement closed in March 2026 after clinical milestone achievement.
- Smital Shah appointed Chief Financial and Business Officer in March 2026.
Financial Impact
Reduced operating expenses and improved cash efficiency: non-GAAP net loss decreased to $33.1M (Q4) and $144.8M (full-year) from $45.9M and $159.5M in 2024. R&D spend decreased on a non-GAAP basis despite LYL273 acquisition costs.
Risk Factors
- High cash burn relative to market cap; future equity offerings likely if trials extend or fail.
- Clinical trial execution risk in large randomized Phase 3 trial (PiNACLE-H2H).
- LYL273 is early-stage with limited data; dose escalation could reveal toxicity.
- Forward-looking statements carry significant uncertainty; no revenue from product candidates yet.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3255090 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
Press Release
| $13.32 awaiting T+20 | awaiting T+20 | — | $13.50 (+1.39%) |
|
Jun 8, 2026
5d ago
|
Press Release
| $11.94 awaiting T+20 | awaiting T+20 | — | $13.50 (+13.11%) |
|
Jun 4, 2026
8d ago
|
Press Release
| $13.02 awaiting T+20 | awaiting T+20 | — | $13.50 (+3.73%) |
|
Apr 24, 2026
7w ago
|
DEFA14A
| $22.62 $16.37 | ▼ −27.63% | ▼ −32.59% | $13.50 (−40.32%) |
|
Apr 15, 2026
8w ago
|
EFFECT
| $23.84 $19.25 | ▼ −19.25% | ▼ −25.30% | $13.50 (−43.37%) |
|
Apr 3, 2026
10w ago
|
S-3
| $21.69 $20.72 | ▼ −4.47% | ▼ −13.45% | $13.50 (−37.76%) |
|
Mar 12, 2026
13w ago
|
Press Release
| $21.25 $24.80 | ▲ +16.71% | ▲ +13.12% | $13.50 (−36.47%) |
|
Mar 9, 2026
13w ago
|
Press Release
| $25.50 $21.78 | ▼ −14.59% | ▼ −11.78% | $13.50 (−47.06%) |
|
Mar 6, 2026
14w ago
|
Insider Cluster
| $22.46 $21.69 | ▼ −3.43% | ▼ −1.38% | $13.50 (−39.89%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $24.10 $19.29 | ▼ −19.96% | ▼ −12.02% | $13.50 (−43.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access